parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocytes; strongest in pericytes	0.75
chemistry Open Targets	hard to drug	0.27
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	6 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 12590

receipt 12597: DLC1 in dopamine neurons, braak

power: full sample +0.29 (p 0.239, n 18), 95% CI -0.20 to +0.67. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.28 (p 0.258, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.29 (p 0.239, n 18). could be the mix.
skeptic: leave-one-out range +0.19 to +0.42, sign flips 0; without severely affected donors +0.29 (p 0.239, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for DLC1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 12596: DLC1 in oligodendrocytes, braak

power: full sample +0.28 (p 0.261, n 18), 95% CI -0.22 to +0.66. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.25 (p 0.323, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.13 (p 0.609, n 18). could be the mix.
skeptic: leave-one-out range +0.17 to +0.46, sign flips 0; without severely affected donors +0.28 (p 0.261, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for DLC1 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts